SCHEMBL10195902

SCHEMBL10195902

Cc1ccc(Nc2nc(Oc3c(C)cc(-c4ccncc4)cc3C)c3cc[nH]c3n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 7/20 0.39
▸ MET P08581 1/20 0.38
▸ CYP2C9 P11712 3/20 0.37
▸ CYP2C19 P33261 3/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ KCNH2 Q12809 2/20 0.37
▸ ABCC3 O15438 1/20 0.37
▸ ESR1 P03372 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ PGR P06401 1/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ ABCB1 P08183 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ DRD1 P21728 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ ABCC1 P33527 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11946965 0.89 CYP2C19 (0.52) PTK2CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL13561245 0.84 HTR2C (0.39) PTK2CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL13561246 0.82 CYP2C9 (0.41) METCYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL1716090 0.78 KCNH2 (0.57) PTK2CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL1716161 0.77 KCNH2 (0.64) PTK2CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL29678152 0.77 KCNH2 (0.64) PTK2CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL13561222 0.76 CYP2C9 (0.37) CYP2C9CYP2C19CYP3A4KCNH2ABCC3
SCHEMBL13561397 0.75 CYP2C9 (0.38) CYP2C9CYP2C19CYP3A4KCNH2ABCC3
SCHEMBL13561393 0.75 CYP2C9 (0.38) CYP2C9CYP2C19CYP3A4KCNH2ABCC3
SCHEMBL4100811 0.75 CYP2C19 (0.51) CYP2C9CYP2C19CYP3A4KCNH2ABCC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372852-B2 Purines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2013-02-12 — — US disclosed
US-20120277206-A1 REVERSE TRANSCRIPTASE INHIBITORS Andrea Boesciences, Inc. (US) 2012-11-01 — — US disclosed
US-8207178-B2 Fused pyrimidines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2012-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277206-A1 REVERSE TRANSCRIPTASE INHIBITORS POLRMT, POLR1E, TYMP PTK2 4460/4885MET 4623/4885CYP2C9 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback